Explore
← New search
Filters:
1
✕
2
✕
pdos from poorly responding patients (nod02, nod05) with uncommon egfr mutations
✕
clear all
1 matching publication(s)
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · Cell Rep Med · 2024
L1
72/100